| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1038298482 |
| P356 | DOI | 10.1007/S40264-014-0225-0 |
| P932 | PMC publication ID | 4206770 |
| P698 | PubMed publication ID | 25255848 |
| P5875 | ResearchGate publication ID | 266248894 |
| P50 | author | Nicholas P. Tatonetti | Q39888223 |
| P2093 | author name string | Colin B Erdman | |
| Keith B Hoffman | |||
| Mo Dimbil | |||
| Andrea R Demakas | |||
| P2860 | cites work | The Lyme vaccine: a cautionary tale | Q22251377 |
| Timing of new black box warnings and withdrawals for prescription medications | Q28216033 | ||
| Exercise and diet reduce risk of diabetes, US study shows | Q28346222 | ||
| Bayer decides to withdraw cholesterol lowering drug | Q28346225 | ||
| Breaking the news or fueling the epidemic? Temporal association between news media report volume and opioid-related mortality | Q28471855 | ||
| Effectiveness of risk management plans: a case study of pemoline using pharmacy claims data | Q31047942 | ||
| Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States | Q31107935 | ||
| The unbearable lightness of health science reporting: a week examining Italian print media | Q33547427 | ||
| Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns? | Q33568855 | ||
| News coverage of FDA warnings on pediatric antidepressant use and suicidality | Q33584737 | ||
| A study of compliance with FDA recommendations for pemoline (Cylert). | Q34137803 | ||
| Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. | Q34342685 | ||
| Adverse drug event monitoring at the Food and Drug Administration | Q34740872 | ||
| Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs. | Q34963164 | ||
| Changes in antidepressant medications prescribing trends in children and adolescents in Hawai'i following the FDA black box warning | Q35015273 | ||
| The impact of wording in "Dear doctor" letters and in black box labels | Q35032495 | ||
| Communication of medical product risk: how effective is effective enough? | Q35778956 | ||
| Non-sedating antihistamine drugs and cardiac arrhythmias -- biased risk estimates from spontaneous reporting systems? | Q35803639 | ||
| Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants | Q35896311 | ||
| Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review | Q35928690 | ||
| Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program | Q35951667 | ||
| The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer | Q36115981 | ||
| Primary care physician attitudes and perceptions of the impact of FDA-proposed REMS policy on prescription of extended-release and long-acting opioids | Q36326428 | ||
| Under-reporting of adverse drug reactions : a systematic review | Q36475336 | ||
| Adherence to black box warnings for prescription medications in outpatients. | Q51819303 | ||
| The effect of antidepressant warnings on prescribing trends in Ontario, Canada. | Q51906428 | ||
| Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database. | Q53142038 | ||
| Coverage by the news media of the benefits and risks of medications. | Q53520692 | ||
| Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome. | Q53674412 | ||
| Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs | Q60148394 | ||
| FDA drug prescribing warnings: is the black box half empty or half full? | Q61836991 | ||
| Contraindicated use of cisapride: impact of food and drug administration regulatory action | Q73310907 | ||
| Drug labeling revisions-guaranteed to fail? | Q73310923 | ||
| Statin safety: an appraisal from the adverse event reporting system | Q83040403 | ||
| Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert | Q83723528 | ||
| The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development | Q36612613 | ||
| Telithromycin: the perils of hasty adoption and persistence of off-label prescribing | Q36867249 | ||
| Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events | Q37240896 | ||
| Determinants of under-reporting of adverse drug reactions: a systematic review. | Q37365382 | ||
| Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA). | Q37488318 | ||
| Sources of drug information: FDA-approved labeling and other official FDA sources | Q37488342 | ||
| ADHD medication use following FDA risk warnings | Q37497927 | ||
| Persisting decline in depression treatment after FDA warnings | Q37504480 | ||
| The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. | Q37683523 | ||
| FDA boxed warnings: how to prescribe drugs safely. | Q37683743 | ||
| Clinical consequences of disseminating the rosiglitazone FDA safety warning. | Q37747333 | ||
| The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper | Q37771430 | ||
| Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression. | Q37790597 | ||
| Impact of safety-related regulatory action on clinical practice: a systematic review. | Q38000336 | ||
| Warnings without guidance: patient responses to an FDA warning about ezetimibe | Q38009690 | ||
| Messages about black-box warnings: a comparative analysis of reports from the FDA and lay media in the US. | Q39928881 | ||
| Responding to an FDA warning--geographic variation in the use of rosiglitazone | Q42806869 | ||
| Evaluation of Adverse Drug Event Information in US Manufacturer Labels | Q43572006 | ||
| Liver enzyme monitoring in patients treated with troglitazone | Q43702652 | ||
| Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias | Q43761720 | ||
| Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy | Q43961933 | ||
| Spontaneous adverse event reports associated with zolpidem in Australia 2001-2008. | Q44123921 | ||
| Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings | Q44259664 | ||
| Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone | Q45037773 | ||
| The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. | Q46493432 | ||
| Effects of Food and Drug Administration warnings on antidepressant use in a national sample | Q46818954 | ||
| Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis | Q46823225 | ||
| Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs | Q46911904 | ||
| A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility | Q48667648 | ||
| The role of scientific evidence of risks and benefits in determining risk management policies for medications | Q50142702 | ||
| Regulatory innovation in postmarketing risk assessment and management | Q50145408 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P304 | page(s) | 971-980 | |
| P577 | publication date | 2014-11-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS) | |
| P478 | volume | 37 |
| Q47285139 | Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports? |
| Q88359245 | Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients |
| Q31114073 | Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data |
| Q55129514 | Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database. |
| Q49559586 | Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India |
| Q38363295 | Drugs and Diseases Interacting with Cigarette Smoking in US Prescription Drug Labelling |
| Q28551405 | Factors Affecting the Timing of Signal Detection of Adverse Drug Reactions |
| Q98290189 | Isotretinoin-Induced Delusional Disorder, Somatic Subtype |
| Q90533450 | Pharmacovigilance of Alternative Medications in the Cancer Setting |
| Q28544621 | Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe |
| Q38635246 | Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets. |
| Q50026480 | Risk Factor for Diabetes Mellitus and High Blood Glucose With HMG-CoA Reductase Inhibitors Using a Postmarketing Surveillance Database in Japan |
| Q36370828 | SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System |
| Q92535970 | Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System |
| Q55433227 | Spontaneous Reporting on Adverse Events by Consumers in the United States: An Analysis of the Food and Drug Administration Adverse Event Reporting System Database. |
| Q30396594 | Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016. |
| Q90374653 | US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS) |
Search more.